Xconomy: Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug
Summary
Jacob Fuchs, an Xconomy reader and pharmacy student interested in the use of C-peptide as a potential treatment for diabetic patients, recently inquired about the company’s status.John Wahren, an emeritus professor of clinical physiology at Sweden’s Karolinska Institute, had helped determine that C-peptide plays a key role in keeping the smallest blood vessels healthy.Cebix was focused on a proprietary replacement peptide, called Ersatta, for treating such complications.“We concluded a perfectly executed phase 2b in December, just to get definitive results that Ersatta and placebo were, alas, indistinguishable,” Martin explained.At that time, Martin said the company had raised a total of nearly $48 million, primarily from InterWest, Sofinnova Ventures, and Thomas, McNerney & Partners.